![Diderik Børsting Schnitler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Diderik Børsting Schnitler
Président chez
NLI AS
Profil
Diderik Børsting Schnitler is currently the Chairman of NLI AS, Stabæk Holding AS, Rainpower AS, Sensorlink AS, Stabæk Drift AS, AlgiPharma Holding AS, AlgiPharma APR AS, and President of Næringslivets Hovedorganisasjon.
He previously served as President & CEO of Saga Petroleum ASA and Krüger Kaldnes AS, Executive Vice President of Kværner ASA, and Chairman of Wallenius Wilhelmsen ASA, Zalaris ASA, Valhalla Oil & Gas AS, Det Norske Oljeselskap ASA, and Wilh.
Wilhelmsen Holding ASA. He was also a Director of Wallenius Wilhelmsen Ocean AS.
He graduated from the Norwegian University of Science & Technology in 1970.
Postes actifs de Diderik Børsting Schnitler
| Sociétés | Poste | Début |
|---|---|---|
NLI AS
 NLI AS Engineering & ConstructionIndustrial Services Provides offshore engineering services | Président | 29/07/2011 |
Rainpower AS
 Rainpower AS Engineering & ConstructionIndustrial Services Operates hydro electric power plants | Président | 29/07/2011 |
Stabæk Holding AS | Président | 29/07/2011 |
Stabæk Drift AS | Président | 29/07/2011 |
AlgiPharma Holding AS
 AlgiPharma Holding AS AlgiPharma Holding AS is a privately owned, Norwegian clinical-stage biopharmaceutical company that specializes in developing proprietary alginate oligosaccharide technology derived from brown seaweed. The company is based in Sandvika, Norway. The company’s platform produces highly purified, GMP-compliant oligosaccharides with properties such as water solubility, stability, non-toxicity, and biocompatibility. This technology is used as a drug delivery platform and as standalone active pharmaceutical ingredients targeting diseases including cystic fibrosis, COPD, infectious diseases, and wound healing. The oligosaccharides help release stagnant mucus, disrupt microbial biofilms, inhibit microbial adherence and virulence, prevent fungal tissue invasion, and enhance therapeutic delivery and efficacy. The technology can also be conjugated with antimicrobials to reduce toxicity without inducing microbial resistance. AlgiPharma has completed six clinical trials for its lead drug candidate targeting cystic fibrosis and maintains a comprehensive preclinical toxicology portfolio supporting multiple formulations for inhalation, oral, intravenous, and topical administration. | Directeur/Membre du Conseil | 29/07/2011 |
AlgiPharma APR AS | Directeur/Membre du Conseil | 29/07/2011 |
Næringslivets Hovedorganisasjon
 Næringslivets Hovedorganisasjon Personnel ServicesCommercial Services Provides emploemnet services | President | - |
Anciens postes connus de Diderik Børsting Schnitler
| Sociétés | Poste | Fin |
|---|---|---|
Sensorlink AS | Président | 02/12/2024 |
Det Norske Oljeselskap ASA /Old/
 Det Norske Oljeselskap ASA /Old/ Oil & Gas ProductionEnergy Minerals Operates a petroleum company | Président | 26/06/2009 |
| ░░░░ ░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Diderik Børsting Schnitler
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
9
Relations au 1er degré
18
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 18 |
|---|---|
WALLENIUS WILHELMSEN ASA
 WALLENIUS WILHELMSEN ASA Marine ShippingTransportation Provides shipping and logistics services & functions as an investment holding company | Transportation |
Wallenius Wilhelmsen Ocean AS
 Wallenius Wilhelmsen Ocean AS Air Freight/CouriersTransportation Provides global factory-to-dealer transport solutions | Transportation |
Saga Petroleum ASA
 Saga Petroleum ASA Oil & Gas ProductionEnergy Minerals Provides oil and gas exploration services | Energy Minerals |
Næringslivets Hovedorganisasjon
Næringslivets Hovedorganisasjon Personnel ServicesCommercial Services Provides emploemnet services | Commercial Services |
Zalaris ASA
 Zalaris ASA Personnel ServicesCommercial Services Provides human capital management and payroll solutions | Commercial Services |
Norwegian University of Science & Technology
 Norwegian University of Science & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Valhalla Oil & Gas AS
 Valhalla Oil & Gas AS Oilfield Services/EquipmentIndustrial Services Indentifies oil and gas opportunities | Industrial Services |
Det Norske Oljeselskap ASA /Old/
Det Norske Oljeselskap ASA /Old/ Oil & Gas ProductionEnergy Minerals Operates a petroleum company | Energy Minerals |
NLI AS
NLI AS Engineering & ConstructionIndustrial Services Provides offshore engineering services | Industrial Services |
Stabæk Holding AS | |
Krüger Kaldnes AS
 Krüger Kaldnes AS Environmental ServicesIndustrial Services Provides wastewater treatment solutions | Industrial Services |
Rainpower AS
Rainpower AS Engineering & ConstructionIndustrial Services Operates hydro electric power plants | Industrial Services |
Wilh. Wilhelmsen Holding ASA
 Wilh. Wilhelmsen Holding ASA Other TransportationTransportation Provides maritime services | Transportation |
Kværner ASA
 Kværner ASA Engineering & ConstructionIndustrial Services Provides engineering, procurement and construction services for offshore platforms and onshore plants | Industrial Services |
Sensorlink AS | |
Stabæk Drift AS | |
AlgiPharma Holding AS
AlgiPharma Holding AS AlgiPharma Holding AS is a privately owned, Norwegian clinical-stage biopharmaceutical company that specializes in developing proprietary alginate oligosaccharide technology derived from brown seaweed. The company is based in Sandvika, Norway. The company’s platform produces highly purified, GMP-compliant oligosaccharides with properties such as water solubility, stability, non-toxicity, and biocompatibility. This technology is used as a drug delivery platform and as standalone active pharmaceutical ingredients targeting diseases including cystic fibrosis, COPD, infectious diseases, and wound healing. The oligosaccharides help release stagnant mucus, disrupt microbial biofilms, inhibit microbial adherence and virulence, prevent fungal tissue invasion, and enhance therapeutic delivery and efficacy. The technology can also be conjugated with antimicrobials to reduce toxicity without inducing microbial resistance. AlgiPharma has completed six clinical trials for its lead drug candidate targeting cystic fibrosis and maintains a comprehensive preclinical toxicology portfolio supporting multiple formulations for inhalation, oral, intravenous, and topical administration. | |
AlgiPharma APR AS |
